Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 249.67B P/E 17.09 EPS this Y 6.60% Ern Qtrly Grth -12.30%
Income 10.62B Forward P/E - EPS next Y 10.20% 50D Avg Chg -2.00%
Sales 60.58B PEG 3.32 EPS past 5Y 4.84% 200D Avg Chg -2.00%
Dividend 25.00% Price/Book 8.75 EPS next 5Y 4.30% 52W High Chg -12.00%
Recommedations 2.00 Quick Ratio 0.80 Shares Outstanding 5.52B 52W Low Chg 10.00%
Insider Own - ROA 12.49% Shares Float 726.97M Beta 0.15
Inst Own 0.28% ROE 36.36% Shares Shorted/Prior -/- Price 38.29
Gross Margin 74.54% Profit Margin 17.53% Avg. Volume 1,977,061 Target Price 44.34
Oper. Margin 35.27% Earnings Date Jul 25 Volume 761,977 Change -0.03%
About ROCHE HOLDINGS AG SPN ADR EACH

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

ROCHE HOLDINGS AG SPN ADR EACH News
07:12 AM ARC and Roche collaborate to enhance NSCLC diagnostics using AI
11/19/24 Roche secures CE mark for ovarian cancer detection test
11/18/24 Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE
11/15/24 Ouch: Why a Healthcare Selloff Really Hurts in Europe
11/13/24 Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing
11/12/24 Flare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in Oncology
11/11/24 Lunit AI diagnostic SCOPE system cuts disease progression by 51%
11/07/24 RHHBY or ABBV: Which Is the Better Value Stock Right Now?
11/07/24 SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program
11/05/24 Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024
11/05/24 Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024
11/04/24 AstraZeneca Says Obesity Pill Shows Minimal Side Effects in Early Trial
11/01/24 Halozyme Therapeutics Inc (HALO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
10/31/24 Roche’s Antibody Against Alzheimer’s Looks the Best Yet
10/31/24 AbbVie’s Deal for Alzheimer’s Antibody Raises Curtain for Roche News on Wednesday
10/31/24 Roche weighs whether speedy approval path is open for latest Alzheimer’s drug
10/31/24 Roche’s Alzheimer’s test shows high negative predictive value
10/31/24 Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease
10/31/24 New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer
10/30/24 New England Journal of Medicine Publishes Landmark Phase III Results for Genentech’s Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast Cancer
RHHBY Chatroom

User Image GreenEnergy2022 Posted - 15 minutes from now

$ALT The Eli Lilly - Laekna news yesterday is bullish for ALT; which has class leading lean mass preservation data. - It proves its important for BP, to acquire next generation GLP1 where patients keep their muscle while losing fat: "China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug" https://finance.yahoo.com/news/china-based-biotech-laekna-teams-151059263.html?guccounter=1 $AMGN $AZN $MRK $RHHBY

User Image lmdxxxxxxxxxx Posted - 9 hours ago

$LMDX $RHHBY My thought is this. The group realized how beneficial their donation helped and some looked to profit. They had a buyer and cleared their debt with it. Now those whom kept their shares will be rewarded from the sale of their remaining patents which I believe are imperative to Roche and the global scale of this operation.

User Image quickaspeter Posted - 15 hours ago

$ALT $LLY $RHHBY Exactly…it’s coming just needs little more patience!!

User Image AnJaMi Posted - 15 hours ago

$LMDX not much else to discuss other than lambos and bugattis...also that $RHHBY went back down again to stockpile cash for us...

User Image D0C_H0LLIDAY Posted - 15 hours ago

$ALT The $LLY deal today is supremely bullish for Altimmune. We often reference the $RHHBY buyout of Carmot as a "floor" value for $ALT, but the $LLY partnership with Laekna (inferior product, foreign, and light years behind in regulatory hurdles) is worth considerably more than our current MC given today's market reaction. Moreover, this illustrates that BP *IS* willing to make deals, regardless of the political climate, and $ALT is arguably the best candidate to be bought out at this time. We are very close IMO.

User Image nextfinancing Posted - 15 hours ago

@JD_Da_Boss I think LMDX just got a 2:1 conversion into $RHHBY

User Image JD_Da_Boss Posted - 15 hours ago

$RHHBY roache is a steaming pile of swiss shit!

User Image nextfinancing Posted - 15 hours ago

@petoss $RHHBY is at $35, so 2:1 = $17.50

User Image PagPag Posted - 19 hours ago

$LMDX $RHHBY It will be extremely dumb if they don't transfer/boyout our shares. Their reputation is at stake at this point. Why pay x10 if you can afford to pay x now, and make it a win/win situation for every party involved (shareholders, creditors, etc.)? Makes no sense to me. They will be hearing from litigation law firms if they eff up in this case. We work hard for our money in order to better the lives of our families and loved ones, and we need our ROI (return on investment) NOW.

User Image THEGOAT83 Posted - 19 hours ago

$LMDX at the end of the day who cares if Mashaal & Gates sold out. Roche owes us money. Time to pay up $RHHBY

User Image JD_Da_Boss Posted - 22 hours ago

$LMDX time to pay us! $RHHBY

User Image Lets_Go_Brndn Posted - 1 day ago

$VKTX BuyOut can’t be ignored. Data pipeline ONE IF THE BEST IF NOT THE BEST IN ALL PHARMACEUTICAL INDUSTRY. Every CEO WILL HAVE to answer why they didn’t attempt to buy it. $RHHBY CEO is on the hot seat. Good luck awful Schniecker.

User Image THEGOAT83 Posted - 1 day ago

$LMDX $rhhby is most likely delaying the deal for regulatory purposes. RonZ most likely wants to delay for tax purposes. They don't really have any other reason to not announce the final terms of the deal unless they're waiting for a specific event. Roche may even try to prolong it until the company is profitable which I don't see that. Most likely the regulatory nonsense & taxes. They can't keep us in the dark forever especially with the new regime looming if Roche wants to stay in good graces with the US.

User Image AnJaMi Posted - 1 day ago

$LMDX $RHHBY up after hours? Time to pay up. Somebody knows what's coming.

User Image TrendRider1 Posted - 1 day ago

$RHHBY what’s this AH pop at 39.56?

User Image Trains224 Posted - 1 day ago

$RHHBY I assume this continues to bleed due to a decline in the perception of Roche's trustworthiness, stemming from questionable treatment of shareholders at Lumira. Wrap that up ethically and up you go.

User Image JD_Da_Boss Posted - 1 day ago

$RHHBY

User Image THEGOAT83 Posted - 1 day ago

$LMDX all I know is $rhhby has ample resources to NOT screw us over. The bears here are silly.

User Image THEGOAT83 Posted - 2 days ago

$FCN FTI shareholders will be fucked courtesy of $LMDX shareholders when the $RHHBY rumble n tumble comes a knocking. 😉😉😉

User Image THEGOAT83 Posted - 2 days ago

$SPY $RHHBY $LMDX How about Roche buying DNEDX and bring pet care into their repertoire.

User Image lmdxxxxxxxxxx Posted - 2 days ago

$LMDX $RHHBY $SPY How much are we looking at? Roche Are you missing other parts that would add much more value to the recent acquisition? Maybe this technology has the capabilities to save so many? Time is of the essence…In order for us to reach this it seems they need all parts. We know LMDX owns other patents that they are selling…. These could be worth billions. LMDX might have set the stage for some leverage on their next deal….. LMDX owes roughly 70mil after the $RHHBY deal. If one of their remaining patents is anywhere near the recent similar sales we could be talking about Billions! Bill and Melinda are not far from this, seems they are not interested in the money. But they may need other parts…. IMO There is something BIG HERE….

User Image THEGOAT83 Posted - 2 days ago

$LMDX I guess $rhhby wants a repeat of $ONCE or go through what $ABT did with Alere??? Doesn't make sense to me.

User Image THEGOAT83 Posted - 2 days ago

$LMDX Roche $RHHBY is a 350B company can't even give us a solid buyout. RHHBY also an ADR of a 350B dollar company. Can't maintain 40.00 Roche is a pile of 💩💩💩

User Image THEGOAT83 Posted - 2 days ago

$FCN $RHHBY

User Image THEGOAT83 Posted - 2 days ago

$RHHBY walking turd deserves .50

User Image JD_Da_Boss Posted - 2 days ago

$LMDX $RHHBY say bye bye to the feckless dickhead Gensler! https://fortune.com/crypto/2024/11/05/gary-genslers-time-as-sec-chair-may-be-coming-to-an-end-who-will-replace-him-and-what-does-it-mean-for-crypto/

User Image Trains224 Posted - 2 days ago

$RHHBY $FCN What do these entities have in common?

User Image THEGOAT83 Posted - 2 days ago

$RHHBY I once believed in this company but now I know they are a sham no better than $PFE

User Image Trains224 Posted - 2 days ago

$LMDX $RHHBY Sorry for sharing all those messages, gang, I know it's obnoxious. But it's time to light 'em up. If they get us to lie down they'll run with what they've done. We will NOT let them get away with it.

User Image Trains224 Posted - 2 days ago

$LMDX $RHHBY $FCN

Analyst Ratings
TD Cowen Market Perform Sep 12, 23
Cowen & Co. Market Perform Nov 15, 22
Cowen & Co. Outperform Jun 27, 22
Deutsche Bank Buy Jul 8, 21
Argus Research Buy Jan 28, 19
Credit Suisse Neutral Jan 28, 19
Goldman Sachs Buy Nov 19, 18
Credit Suisse Underperform May 25, 18
Bernstein Market Perform May 10, 18